Adaptive biotechnologies stock.

Nov 30, 2023 · Adaptive Biotechnologies Corp ADPT Morningstar Rating Unlock Stock XNAS Rating as of Nov 30, 2023 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Financials Valuation... Oct 19, 2023 · Adaptive Biotechnologies Corp does not have a meaningful P/E due to negative earnings over the last 12 trailing months. Adaptive Biotechnologies Corp’s trailing 12-month revenue is $189.6 million with a -100.7% profit margin. Year-over-year quarterly sales growth most recently was 11.9%. Revenue was $37.6 million for the quarter ended March 31, 2023, representing a 3% decrease from the first quarter in the prior year. Immune Medicine revenue was $16.2 million for the quarter, representing a 22% decrease from the first quarter in the prior year mainly driven by a decline in amortization of the Genentech upfront payment.Stock Price Forecast. The 6 analysts offering 12-month price forecasts for Adaptive Biotechnologies Corp have a median target of 10.00, with a high estimate of 11.00 and a low estimate of 6.00 ...

Adaptive Biotechnologies Stock Performance. NASDAQ:ADPT opened at $4.33 on Tuesday. The firm’s fifty day moving average is $4.59 and its two-hundred day moving average is $6.13. Adaptive Biotechnologies Co. has a one year low of $2.61 and a one year high of $10.79. The firm has a market cap of $626.85 million, a price-to …Get the latest Adaptive Biotechnologies Corporation (ADPT) stock price, news, buy or sell recommendation, and investing advice from Wall Street professionals.

Adaptive Biotechnologies Corporation Registered Shs's market capitalization is $631.55 M by 144.64 M shares outstanding. Adaptive Biotechnologies …Delmaine Donson. Adaptive Biotechnologies (NASDAQ:ADPT) stock fell ~10% on Tuesday after the company said it is terminating the services of its Chief Operating Officer Mark Adams by May.The ...

Shares of Adaptive Biotechnologies (ADPT) have gained 1.3% over the past four weeks to close the last trading session at $8.89, but there could still be a solid upside left in the stock if short ...Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call Transcript November 9, 2023 Adaptive Biotechnologies Corporation misses on earnings expectations. Reported EPS is $-0.35 ...Adaptive Biotechnologies Corp. ( NASDAQ: ADPT) stock is down over 72% in the previous 52-weeks and 58.5% YTD. Since its inception, the company has been a loss-maker. Still, the revenues have been ...Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...Adaptive Biotechnologies to Report Third Quarter Financial Results on November 9, 2023. SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose …

SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to …

Bluebird Bio. Market Cap. $466M. Today's Change. (11.52%) $0.44. Current Price. $4.26. Price as of December 1, 2023, 4:00 p.m. ET. You’re reading a free …

Adaptive Biotechnologies Corporation . 2019 Employee Stock Purchase Plan . 1. ESTABLISHMENT, PURPOSE AND TERM OF PLAN.. 1.1 Establishment. The Adaptive Biotechnologies Corporation 2019 Employee Stock Purchase Plan is hereby established effective as of the effective date of the initial registration by the Company of its Stock …Traditional biotechnology is the use of natural organisms by humans to create or modify foods or other useful products. Examples of traditional biotechnology include using yeasts for fermentation and practicing selective seed collection to ...What percentage of Adaptive Biotechnologies stock is owned by insiders? 5.20% of Adaptive Biotechnologies stock is owned by insiders. Learn more on ADPT's insider holdings.SEATTLE, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced a multi-year, global translational collaboration with BeiGene to …Apr 15, 2022 · Adaptive Biotechnologies sports a market-leading advantage with its one-of-a-kind proprietary tech. The company's stock has been smashed in the last year losing over two-thirds of its share price.

Find the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing.Earnings for Adaptive Biotechnologies are expected to grow in the coming year, from ($1.35) to ($1.10) per share. Adaptive Biotechnologies has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 13th, 2024 based off prior year's report dates. Read More.View the latest Adaptive Biotechnologies Corp. (ADPT) stock price, news, historical charts, analyst ratings and financial information from WSJ. SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it has entered into a translational collaboration with Takeda to …Get the latest Adaptive Biotechnologies Corporation (ADPT) stock quote, history, news and other vital information to help you with your stock trading and investing. See the performance outlook, earnings date, dividend yield, research reports and more for ADPT on NasdaqGS. The latest closing stock price for Adaptive Biotechnologies as of November 24, 2023 is 4.37. The all-time high Adaptive Biotechnologies stock closing price was 67.74 on …Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call Transcript November 9, 2023 Adaptive Biotechnologies Corporation misses on earnings expectations. Reported EPS is $-0.35 ...

SEATTLE, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pricing of its underwritten public …Employment: Adaptive Biotechnologies. Stock and Other Ownership Interests: Adaptive Biotechnologies. Lik Wee Lee. Employment: Adaptive Biotechnologies. Crystal L. Mackall. Stock and Other Ownership Interests: Lyell Immunopharma, Alimera Sciences, Vor Pharmaceuticals, Apricity Health, Syncopation …

Adaptive Biotechnologies Corporation Common Stock (ADPT) Stock Price, Quote, News & History | Nasdaq MY QUOTES: ADPT Edit my quotes Adaptive Biotechnologies Corporation Common...Inside the Adaptive Biotech IPO: How two brothers built a big idea into a breakthrough company by James Thorne on June 2, 2019 at 10:52 am June 4, 2019 at 3:28 pm Share 18 Tweet Share Reddit EmailSo consider, for a moment, the misfortune of Adaptive Biotechnologies Corporation (NASDAQ:ADPT) investors who have held the stock for three years as it declined a whopping 82%.Adaptive Biotechnologies (ADPT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the ...Adaptive Biotechnologies (ADPT) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? A quick glance at the ...The estimated net worth of Chad M. Cohen is at least $134,139.07 as of September 7th, 2021. Mr. Cohen owns 30,979 shares of Adaptive Biotechnologies stock worth more than $134,139 as of November 28th. This net worth evaluation does not reflect any other investments that Mr. Cohen may own. Learn More about Chad M. Cohen's net …Adaptive Biotechnologies Corporation (NASDAQ:ADPT) Q3 2023 Earnings Call Transcript November 9, 2023 Adaptive Biotechnologies Corporation misses on earnings expectations. Reported EPS is $-0.35 ...

Track Adaptive Biotechnologies Corp (ADPT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors

Adaptive Biotechnologies Corp. company facts, information and financial ratios from MarketWatch. ... 6:33a Bilibili started at buy with $18 stock price target at Mizuho

Adaptive Biotechnologies Corp. company facts, information and financial ratios from MarketWatch. ... 6:33a Bilibili started at buy with $18 stock price target at MizuhoOn average, Wall Street analysts predict. that Adaptive Biotechnologies's share price could reach $8.00 by Nov 13, 2024. The average Adaptive Biotechnologies stock price prediction forecasts a potential upside of 83.07% from …Dec 1, 2023 · A high-level overview of Adaptive Biotechnologies Corporation (ADPT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Adaptive Biotechnologies Corporation will report financial results for Q3 2023 on November 9, 2023. The company aims to translate the genetics of t...A high-level overview of Adaptive Biotechnologies Corporation (ADPT) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.SEATTLE, Jan. 23, 2020 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pricing of its underwritten public …In the past three months, Adaptive Biotechnologies insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,070.00 in company stock. Percentage Held by Insiders. Only 5.20% of the stock of Adaptive Biotechnologies is held by insiders. Percentage Held by InstitutionsIt should be noted that over the last three months, corporate insiders have sold a total of 248,613 shares of Adaptive Biotechnologies stock, with a cumulative value of $2,006,083. As a result, corporate insiders now hold 5.20% of the company’s stock.Adaptive Biotechnologies: Stock Isn't Cheap. Jun. 04, 2021 4:10 PM ET Adaptive Biotechnologies Corporation (ADPT) 7 Comments 3 Likes. Avisol Capital Partners. Investing Group Leader. Follow.

Find the latest Institutional Holdings data for Adaptive Biotechnologies Corporation Common Stock (ADPT) at Nasdaq.com.Adaptive Biotechnologies Corp is down 9.82% from its previous closing price of $8.25. During the last market session, Adaptive Biotechnologies Corp’s stock traded between $8.20 and $8.61. Currently, there are 143.06 million shares of Adaptive Biotechnologies Corp stock available for purchase. Unfortunately, Adaptive Biotechnologies Corp’s P ...Adaptive Biotechnologies Condensed Consolidated Statements of Operations (in thousands, except share and per share amounts) ... Common stock: $0.0001 par value, 340,000,000 shares authorized at June 30, 2021 and December 31, 2020; 140,663,755 and 137,646,896 shares issued and outstanding at June 30, 2021 and …Instagram:https://instagram. nextfplatinum miners stockstorov stocksepelios Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines. The company was founded by Chad Robins, Harlan Robins, and Chris Carlson on September 8, 2009 and is headquartered in Seattle, WA. Insider Trading. Relationship. … lon bptlt.stock SEATTLE, Dec. 01, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced the launch of its clonoSEQ ® Assay to detect minimal residual disease ... best crypto tracker Adaptive Biotechnologies (ADPT) Stock Forecast & Price TargetSEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it has entered into a translational collaboration with Takeda to …